Your browser doesn't support javascript.
loading
Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype-phenotype correlations, codon bias and dominant-negative effects.
Hannan, Fadil M; Howles, Sarah A; Rogers, Angela; Cranston, Treena; Gorvin, Caroline M; Babinsky, Valerie N; Reed, Anita A; Thakker, Clare E; Bockenhauer, Detlef; Brown, Rosalind S; Connell, John M; Cook, Jacqueline; Darzy, Ken; Ehtisham, Sarah; Graham, Una; Hulse, Tony; Hunter, Steven J; Izatt, Louise; Kumar, Dhavendra; McKenna, Malachi J; McKnight, John A; Morrison, Patrick J; Mughal, M Zulf; O'Halloran, Domhnall; Pearce, Simon H; Porteous, Mary E; Rahman, Mushtaqur; Richardson, Tristan; Robinson, Robert; Scheers, Isabelle; Siddique, Haroon; Van't Hoff, William G; Wang, Timothy; Whyte, Michael P; Nesbit, M Andrew; Thakker, Rajesh V.
Afiliación
  • Hannan FM; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Howles SA; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Rogers A; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Cranston T; Oxford Molecular Genetics Laboratory, Churchill Hospital, Oxford, UK.
  • Gorvin CM; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Babinsky VN; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Reed AA; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Thakker CE; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Bockenhauer D; Renal Unit, Great Ormond Street Hospital for Children NHS Foundation Trust and UCL Institute of Child Health, London, UK.
  • Brown RS; Division of Endocrinology, Boston Children's Hospital, Boston, MA, USA.
  • Connell JM; School of Medicine, Ninewells Hospital, University of Dundee, Dundee, UK.
  • Cook J; Clinical Genetics Department, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.
  • Darzy K; Queen Elizabeth II Hospital, Welwyn Garden City, UK.
  • Ehtisham S; Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK.
  • Graham U; Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK.
  • Hulse T; Department of Paediatrics, Evelina London Children's Hospital, St. Thomas' Hospital, London, UK.
  • Hunter SJ; Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK.
  • Izatt L; Department of Clinical Genetics, Guy's Hospital, London, UK.
  • Kumar D; Institute of Cancer and Genetics, University Hospital of Wales, Cardiff, UK.
  • McKenna MJ; Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland.
  • McKnight JA; Metabolic Unit, Western General Hospital, NHS Lothian and University of Edinburgh, Edinburgh, UK.
  • Morrison PJ; Centre for Cancer Research and Cell Biology, Queens University of Belfast, Belfast, UK, Department of Genetic Medicine, Belfast HSC Trust, Belfast, UK.
  • Mughal MZ; Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester, UK.
  • O'Halloran D; Department of Endocrinology, Cork University Hospital, Cork, Ireland.
  • Pearce SH; Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
  • Porteous ME; SE Scotland Genetic Service, Western General Hospital, Edinburgh, UK.
  • Rahman M; Department of Endocrinology, Northwick Park Hospital, London, UK.
  • Richardson T; Diabetes and Endocrine Centre, Royal Bournemouth Hospital, Bournemouth, UK.
  • Robinson R; Department of Endocrinology, Chesterfield Royal Hospital NHS Foundation Trust, Derbyshire, UK.
  • Scheers I; Pediatric Gastroenterology, Hepatology and Nutrition Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Siddique H; Department of Endocrinology, Russells Hall Hospital, Dudley, UK.
  • Van't Hoff WG; Renal Unit, Great Ormond Street Hospital for Children NHS Foundation Trust and UCL Institute of Child Health, London, UK.
  • Wang T; Department of Clinical Biochemistry, Frimley Park Hospital, Surrey, UK and.
  • Whyte MP; Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St. Louis, Missouri, USA.
  • Nesbit MA; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Thakker RV; Academic Endocrine Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK, rajesh.thakker@ndm.ox.ac.uk.
Hum Mol Genet ; 24(18): 5079-92, 2015 Sep 15.
Article en En | MEDLINE | ID: mdl-26082470
ABSTRACT
The adaptor protein-2 sigma subunit (AP2σ2) is pivotal for clathrin-mediated endocytosis of plasma membrane constituents such as the calcium-sensing receptor (CaSR). Mutations of the AP2σ2 Arg15 residue result in familial hypocalciuric hypercalcaemia type 3 (FHH3), a disorder of extracellular calcium (Ca(2+) o) homeostasis. To elucidate the role of AP2σ2 in Ca(2+) o regulation, we investigated 65 FHH probands, without other FHH-associated mutations, for AP2σ2 mutations, characterized their functional consequences and investigated the genetic mechanisms leading to FHH3. AP2σ2 mutations were identified in 17 probands, comprising 5 Arg15Cys, 4 Arg15His and 8 Arg15Leu mutations. A genotype-phenotype correlation was observed with the Arg15Leu mutation leading to marked hypercalcaemia. FHH3 probands harboured additional phenotypes such as cognitive dysfunction. All three FHH3-causing AP2σ2 mutations impaired CaSR signal transduction in a dominant-negative manner. Mutational bias was observed at the AP2σ2 Arg15 residue as other predicted missense substitutions (Arg15Gly, Arg15Pro and Arg15Ser), which also caused CaSR loss-of-function, were not detected in FHH probands, and these mutations were found to reduce the numbers of CaSR-expressing cells. FHH3 probands had significantly greater serum calcium (sCa) and magnesium (sMg) concentrations with reduced urinary calcium to creatinine clearance ratios (CCCR) in comparison with FHH1 probands with CaSR mutations, and a calculated index of sCa × sMg/100 × CCCR, which was ≥ 5.0, had a diagnostic sensitivity and specificity of 83 and 86%, respectively, for FHH3. Thus, our studies demonstrate AP2σ2 mutations to result in a more severe FHH phenotype with genotype-phenotype correlations, and a dominant-negative mechanism of action with mutational bias at the Arg15 residue.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Codón / Complejo 2 de Proteína Adaptadora / Subunidades sigma de Complejo de Proteína Adaptadora / Estudios de Asociación Genética / Genes Dominantes / Hipercalcemia / Mutación Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Hum Mol Genet Asunto de la revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Codón / Complejo 2 de Proteína Adaptadora / Subunidades sigma de Complejo de Proteína Adaptadora / Estudios de Asociación Genética / Genes Dominantes / Hipercalcemia / Mutación Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Hum Mol Genet Asunto de la revista: BIOLOGIA MOLECULAR / GENETICA MEDICA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido